Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000694024 | SCV000822449 | pathogenic | Hereditary spastic paraplegia 11 | 2023-04-22 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 572602). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 23733235). This variant is present in population databases (rs141263564, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Lys2200*) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). |
Genome Diagnostics Laboratory, |
RCV001849059 | SCV002105759 | pathogenic | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000694024 | SCV002763692 | pathogenic | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing | ||
Genetics and Molecular Pathology, |
RCV003447554 | SCV004175441 | pathogenic | Early-onset Parkinson disease 20 | 2023-02-15 | criteria provided, single submitter | clinical testing | |
Molecular Genetics Lab, |
RCV003883160 | SCV004697603 | pathogenic | Amyotrophic lateral sclerosis type 5; Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X | criteria provided, single submitter | clinical testing | ||
Mayo Clinic Laboratories, |
RCV004792389 | SCV005414258 | pathogenic | not provided | 2024-07-30 | criteria provided, single submitter | clinical testing | PM2, PM3, PVS1 |
Prevention |
RCV003411614 | SCV004113359 | pathogenic | SPG11-related disorder | 2024-09-05 | no assertion criteria provided | clinical testing | The SPG11 c.6598A>T variant is predicted to result in premature protein termination (p.Lys2200*). This variant was reported in the compound heterozygous state with another loss-of-function variant in two patients with autosomal recessive spastic paraplegia (Yoon et al. 2013. PubMed ID: 23733235; Carrasco Salas et al. 2022. PubMed ID: 33059505). This variant is reported in 0.0039% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in SPG11 are expected to be pathogenic. This variant is interpreted as pathogenic. |
Solve- |
RCV004768574 | SCV005091440 | likely pathogenic | Charcot-Marie-Tooth disease axonal type 2X | 2022-06-01 | no assertion criteria provided | provider interpretation | Variant confirmed as disease-causing by referring clinical team |